This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Amgen Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Qahera Munaim: Innovator in Pharmaceutical Formulations
Introduction
Qahera Munaim is a notable inventor based in Chatsworth, CA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of therapeutic protein formulations. With a total of 2 patents, Munaim's work is focused on enhancing the stability and efficacy of pharmaceutical compounds.
Latest Patents
Munaim's latest patents include innovative formulations that address critical challenges in the pharmaceutical industry. One of his patents is for "Reduced viscosity protein pharmaceutical formulations," which describes therapeutic protein formulations comprising N-methyl pyrrolidone (NMP). This invention outlines methods related to reducing viscosity and stabilizing pharmaceutical formulations using NMP. Another significant patent is for "Stable compositions of pegylated carfilzomib compounds." This invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing these compositions, and their uses in treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to a dry solid form.
Career Highlights
Munaim is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to focus on developing innovative solutions that improve patient outcomes through advanced pharmaceutical formulations.
Collaborations
Some of Munaim's coworkers include Alona Teran and William Callahan, who contribute to the collaborative environment at Amgen Inc. Their combined expertise fosters innovation and drives the development of new therapeutic solutions.
Conclusion
Qahera Munaim's contributions to pharmaceutical formulations demonstrate his commitment to advancing medical science. His innovative patents reflect a deep understanding of the complexities involved in drug formulation and stability. Munaim's work continues to impact the field positively, paving the way for future advancements in cancer treatment.